Project Grant HT94252410310
Award Date
9/30/24
Completion Date
9/29/27
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10022, USA
Similar Awards
This $312,610 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant is funding research at Weill Medical College of Cornell University to investigate the "Role of Functional Factors in AR Reprogramming and Progression of Prostate Cancer." The project aims to advance understanding of prostate cancer biology and explore potential therapeutic interventions. The award has a performance...
The federal Project Grant award in the amount of $847,501.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Weill Medical College of Cornell University. The grant supports research on BCL-XL in breast cancer metastasis and therapy, with a performance period from August 1, 2024 to July 31, 2027. As a leading academic medical institution, the Weill Medical College of Cornell University will leverage its extensive...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $988,740.00 to Weill Medical College of Cornell University. The award supports research focused on "GENOMICALLY INFORMED MORPHOLOGICAL STROMAL SIGNATURES TO PREDICT LETHAL PROSTATE CANCER" with a performance period from June 15, 2025 to June 14, 2028. As a prestigious academic medical institution, Weill Medical College of...
The U.S. Defense Health Agency awarded a $1,522,278 Project Grant to Weill Medical College of Cornell University on September 30, 2024 under the Military Medical Research and Development program (CFDA 12.420). The grant supports a research project titled "Decoding Bone Metastasis in Prostate Cancer: A Multimodal Approach Integrating Genomics and Imaging Data." The project aims to advance scientific understanding and improve treatment of bone metastasis in prostate cancer patients...
This $677,998 federal Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), is funding research at Weill Medical College of Cornell University to target extrachromosomal DNA (ecDNA) to reverse therapy resistance in urothelial cancer. The research aims to investigate innovative approaches to disease prevention, diagnosis, treatment, and management of conditions relevant to military personnel and veterans....
The Defense Health Agency awarded a $808,141 Project Grant to Weill Medical College of Cornell University under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, with a performance period from February 1, 2025 to January 31, 2027, supports research targeting inflammatory pathways in breast cancer brain metastases to develop treatments for edema and radiation necrosis using anti-VEGF ultrasmall particle therapy. As a prominent research institution,...
This $1,356,000.00 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports advanced biomedical research at Weill Medical College of Cornell University focused on the restoration of clear cell renal cell carcinoma tumorigenicity through cell reprogramming. The award spans a 4-year period from November 1, 2024 to October 31, 2028 and provides funding for the institution's cutting-edge...
This $2,542,500.00 federal Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research on therapeutic targeting of the tumor microenvironment in triple-negative breast cancer patients at high risk of relapse and preclinical models of lung metastases. The grant was awarded to Weill Medical College of Cornell University, a prominent academic medical institution, with a performance period from May 15, 2025...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $762,750.00 to Weill Medical College of Cornell University to support "NUTRITION-BASED PROGRAMMING OF DENDRITIC CELLS FOR OVARIAN CANCER IMMUNOTHERAPY" research. The award period runs from May 1, 2025 to April 30, 2028. As a prominent academic medical institution, Weill Medical College of Cornell University will leverage its...
The Department of the Army Medical Command awarded a $762,750 Project Grant to Weill Medical College of Cornell University under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will fund research on perk-driven stress responses that regulate dendritic cell function in ovarian cancer. Through June 2024, Weill Medical College will investigate how stress responses impact immune cell activity and how this relationship influences ovarian cancer progression....